All IndicationsPhase 3Phase 3Phase 3Phase 2
weight-loss
9
Companies
12
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
HNPHY
Hansoh Pharma
Olatorepatide
HNPHY
Hansoh
olatorepatida
LLY
Eli Lilly
retatrutide
TRAX
Ritter Pharmaceuticals
petrelintide
LLY
Eli Lilly
tirzepatide
DMIIR
DMIIR
Weight Loss Products
HIMS
Hims & Hers Health
AI Weight Loss Care
1672
Ascletis Pharma Inc.
ASC36_35FDC
RHHBY
Roche
enicepatide
NVO
Novo Nordisk
semaglutide
PFE
Pfizer
Lipitor
1672
Ascletis Pharma Inc.
ASC36_35 co-formulation
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| HNPHY Hansoh Pharma | Olatorepatide | Phase 3 | — | — | — |
| HNPHY Hansoh | olatorepatida | Phase 3 | — | — | — |
| LLY Eli Lilly | retatrutide | Phase 3 | — | — | — |
| TRAX Ritter Pharmaceuticals | petrelintide | Phase 2 | — | — | — |
| LLY Eli Lilly | tirzepatide | — | — | — | — |
| DMIIR DMIIR | Weight Loss Products | — | — | — | — |
| HIMS Hims & Hers Health | AI Weight Loss Care | — | — | — | — |
| 1672 Ascletis Pharma Inc. | ASC36_35FDC | — | — | — | — |
| RHHBY Roche | enicepatide | — | — | — | — |
| NVO Novo Nordisk | semaglutide | — | — | — | — |
| PFE Pfizer | Lipitor | — | — | — | — |
| 1672 Ascletis Pharma Inc. | ASC36_35 co-formulation | — | — | — | — |
Development Stage Distribution
Unknown
8
Phase 3
3
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.